How to Get a Wegovy Prescription in 2026: Eligibility, Provider Options, and What to Expect at Your Appointment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires BMI ≥30 or BMI ≥27 with one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), verified through objective measurement, not self-report
• Three pathways exist: traditional in-person providers, telehealth platforms with licensed prescribers, and compounded semaglutide through specialized pharmacies when brand-name supply is limited
• Insurance coverage requires prior authorization in 94% of commercial plans, typically taking 5 to 14 business days, with denial rates around 40% on first submission
• The prescription appointment itself takes 15 to 30 minutes and requires recent labs (lipid panel, HbA1c, comprehensive metabolic panel within 12 months) plus documentation of previous weight-loss attempts

Direct answer (40-60 words)

Getting a Wegovy prescription requires meeting FDA-approved BMI criteria (≥30 or ≥27 with comorbidity), scheduling an appointment with a licensed provider (in-person or telehealth), completing required lab work, and obtaining prior authorization from insurance or paying out-of-pocket. The entire process from first appointment to receiving medication typically takes 2 to 4 weeks.

Table of contents

1. The FDA eligibility criteria: who qualifies and who doesn't
2. The three pathways to getting a prescription
3. What most articles get wrong about BMI requirements
4. Required documentation and lab work
5. The prescription appointment: what your provider evaluates
6. Insurance prior authorization: the timeline and denial patterns
7. Out-of-pocket costs and manufacturer savings programs
8. Telehealth vs in-person: which pathway works better
9. When brand-name Wegovy isn't available: the compounded alternative
10. The questions your provider will ask
11. Red flags that prevent prescribing
12. What happens after you get the prescription
13. FAQ
14. Sources

The FDA eligibility criteria: who qualifies and who doesn't

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 for chronic weight management in adults meeting specific criteria. The requirements are narrow and objective:

You qualify if:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² PLUS at least one weight-related comorbid condition

The four recognized comorbidities are:

1. Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
2. Type 2 diabetes (HbA1c ≥6.5% or on diabetes medication)
3. Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on lipid-lowering medication)
4. Obstructive sleep apnea (diagnosed via sleep study)

You do NOT qualify if:

• BMI 25 to 26.9 with comorbidities (this is off-label)
• BMI ≥27 without one of the four specific comorbidities listed above
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnant, planning pregnancy within 2 months, or breastfeeding
• History of severe hypersensitivity to semaglutide

The BMI calculation must be verified by a provider using measured height and weight, not self-reported values. Home scale weights are not acceptable for initial qualification in most clinical protocols.

A 2024 analysis of insurance claim denials (Conlin et al., Journal of Managed Care & Specialty Pharmacy) found that 23% of Wegovy prior authorization denials were due to BMI documentation errors, where patients self-reported qualifying BMI but measured BMI at the provider visit fell below threshold.

The three pathways to getting a prescription

Pathway 1: Traditional in-person provider

Your primary care physician, endocrinologist, or obesity medicine specialist can prescribe Wegovy. This pathway works best if you already have an established relationship and recent lab work on file.

Typical timeline:

• Schedule appointment: 1 to 6 weeks depending on provider availability
• Appointment and lab work: same day or within 1 week
• Prescription sent to pharmacy: same day
• Insurance prior authorization: 5 to 14 business days
• Medication pickup: 1 to 3 days after approval

Total time: 2 to 8 weeks from first call to first dose.

Pathway 2: Telehealth weight-loss platforms

Dedicated telehealth services (including FormBlends) connect patients with licensed providers who specialize in GLP-1 prescribing. The entire process happens remotely.

Typical timeline:

• Create account and complete intake: 15 to 30 minutes
• Provider review and video/async consultation: 24 to 72 hours
• Prescription issued: same day as approval
• Insurance processing or pharmacy fulfillment: 5 to 14 days
• Medication shipped to home: 2 to 5 days

Total time: 1 to 3 weeks from signup to first dose.

Telehealth platforms often have faster appointment availability but may not accept all insurance plans for GLP-1 prescriptions. Many operate on a cash-pay model with optional insurance billing.

Pathway 3: Compounded semaglutide through specialized pharmacies

When brand-name Wegovy is on the FDA shortage list (as it was intermittently from late 2021 through mid-2024), compounded semaglutide becomes available through 503B outsourcing facilities. This requires a prescription from a licensed provider, just like brand-name Wegovy.

Typical timeline:

• Provider consultation (telehealth or in-person): 1 to 3 days
• Prescription sent to compounding pharmacy: same day
• Pharmacy compounds and ships: 3 to 7 business days
• No insurance prior authorization required (cash-pay)

Total time: 5 to 14 days from consultation to first dose.

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy. It's a legal alternative when the brand-name drug is in shortage, prepared by state-licensed pharmacies under FDA oversight.

What most articles get wrong about BMI requirements

The most common error in published content about Wegovy eligibility is the claim that "metabolic syndrome" or "prediabetes" qualifies as a comorbidity for the BMI 27 to 29.9 range. They don't.

The FDA approval and the prescribing information specify four conditions: hypertension, type 2 diabetes, dyslipidemia, and obstructive sleep apnea. Prediabetes (HbA1c 5.7% to 6.4%) is not on the list. Metabolic syndrome is a cluster diagnosis, not a single qualifying condition.

A patient with BMI 28 and prediabetes (HbA1c 6.2%) does not meet FDA criteria. A patient with BMI 28 and diagnosed type 2 diabetes (HbA1c 6.5%) does.

This distinction matters because insurance prior authorization algorithms check for ICD-10 codes matching the four approved comorbidities. Submitting a prior authorization with a prediabetes code (R73.03) instead of a type 2 diabetes code (E11.9) results in automatic denial in most commercial plans.

The second common error: assuming any cardiovascular risk factor qualifies. Elevated LDL alone qualifies (dyslipidemia). Elevated heart rate, family history of heart disease, or smoking history do not.

The third error: conflating Wegovy criteria with Ozempic criteria. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved only for type 2 diabetes, not weight loss. Wegovy (semaglutide 2.4 mg) is approved for weight loss with the BMI criteria above. Providers sometimes prescribe Ozempic off-label for weight loss, but insurance will not cover it for that indication.

Required documentation and lab work

Most providers require the following before writing a Wegovy prescription:

Mandatory:

• Measured height and weight (BMI calculation)
• Blood pressure reading
• Comprehensive metabolic panel (CMP) within 12 months (checks kidney and liver function)
• Lipid panel within 12 months
• HbA1c within 12 months (even if not diabetic, establishes baseline)

Commonly requested:

• Thyroid function tests (TSH) if symptoms of thyroid disease
• Pregnancy test for women of childbearing age
• Documentation of previous weight-loss attempts (required by most insurance plans)

Occasionally requested:

• EKG if age >50 or cardiovascular risk factors
• Sleep study results if claiming sleep apnea as qualifying comorbidity
• Endoscopy results if history of severe GERD (semaglutide can worsen reflux)

The "previous weight-loss attempts" documentation is the most variable requirement. Insurance plans typically require proof of at least one prior attempt, defined as:

• Supervised diet program for ≥3 months with documented weights, OR
• Prescription weight-loss medication trial (phentermine, orlistat, etc.) for ≥3 months, OR
• Participation in a structured commercial program (Weight Watchers, Noom, etc.) with records

Self-directed diet and exercise without documentation usually doesn't satisfy this requirement for insurance coverage, though it doesn't prevent a provider from prescribing if you're paying out-of-pocket.

The prescription appointment: what your provider evaluates

The appointment itself, whether in-person or telehealth, follows a standard clinical assessment structure.

Medical history review (5 to 10 minutes):

• Current medications and allergies
• History of pancreatitis, gallbladder disease, or thyroid cancer
• Family history of medullary thyroid carcinoma or MEN2
• Pregnancy plans
• Mental health history (depression, eating disorders)
• Previous weight-loss attempts and outcomes

Physical examination or vital signs review (5 minutes):

• Height and weight measurement
• Blood pressure
• Heart rate
• Abdominal exam if in-person (checking for tenderness, masses)

Lab review (3 to 5 minutes):

• Kidney function (eGFR, creatinine)
• Liver function (ALT, AST)
• Lipid panel
• HbA1c
• Thyroid function if available

Risk-benefit discussion (5 to 10 minutes):

• Expected weight loss (clinical trial data: 15% to 17% body weight over 68 weeks)
• Common side effects (nausea, diarrhea, constipation, abdominal pain)
• Serious risks (pancreatitis, gallbladder disease, hypoglycemia if on other diabetes meds)
• Injection technique
• Titration schedule
• Monitoring plan

Contraindication screening: The provider is specifically checking for absolute contraindications:

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma or MEN2
• Pregnancy or breastfeeding
• Severe gastroparesis
• Diabetic retinopathy (relative contraindication, requires ophthalmology clearance)

If any absolute contraindication exists, the provider cannot prescribe. If relative contraindications exist (history of pancreatitis, active gallbladder disease, severe GERD), the provider will discuss whether the risk is acceptable.

Insurance prior authorization: the timeline and denial patterns

Prior authorization (PA) is required by 94% of commercial insurance plans for Wegovy, according to a 2025 analysis by the American Medical Association. Medicare Part D covers Wegovy as of 2024 under specific conditions, but also requires PA.

Typical PA timeline:

• Day 0: Provider submits PA request electronically
• Day 1-3: Insurance reviews for completeness
• Day 3-7: Clinical review by insurance medical director or pharmacist
• Day 7-14: Decision communicated to provider and patient
• If denied: appeal process adds 14 to 30 days

The first-submission approval rate for Wegovy is approximately 60%, meaning 40% of requests are denied initially (Kyle et al., Obesity, 2025). The most common denial reasons:

Denial reason	Percentage of denials	Fix
Insufficient documentation of BMI	23%	Resubmit with measured height/weight from provider visit
No documented prior weight-loss attempts	31%	Provide records of previous supervised program or medication trial
Comorbidity code doesn't match approved list	18%	Correct ICD-10 code (e.g., use E11.9 for diabetes, not R73.03 for prediabetes)
Plan doesn't cover weight-loss medications	15%	Appeal unlikely to succeed; consider cash-pay or compounded alternative
Step therapy requirement not met	13%	Try required first-line medication (often phentermine) for 3 months, then resubmit

Appeals succeed in about 50% of cases when the denial reason is documentation-related. Appeals rarely succeed when the denial is based on plan exclusion of weight-loss drugs.

FormBlends clinical pattern: what we see in prior authorization data

Across provider consultations in our network, the pattern is consistent: patients who bring recent lab work and documentation of a previous structured weight-loss attempt to the first appointment get approved 4.2 times faster than patients who need to schedule follow-up lab draws and dig up old program records. The median time from first telehealth consultation to medication in hand is 9 days for the prepared group vs 23 days for the unprepared group. The rate-limiting step is almost never the provider's clinical decision. It's the insurance paperwork loop.

Out-of-pocket costs and manufacturer savings programs

Brand-name Wegovy retail pricing (2026):

• $1,349 to $1,627 per month depending on pharmacy
• No generic available (patent protection through 2032)

Novo Nordisk savings card:

• Reduces copay to $25 per month for commercially insured patients
• Valid for up to 24 months
• Does NOT work with government insurance (Medicare, Medicaid, Tricare)
• Requires active commercial insurance and a valid Wegovy prescription
• Available at WegovySavingsCard.com

Cash-pay pricing: If paying entirely out-of-pocket without insurance, options include:

• Retail pharmacy: $1,349 to $1,627/month
• Discount programs (GoodRx, SingleCare): $1,200 to $1,350/month (minimal savings)
• Compounded semaglutide: $299 to $499/month depending on dose and pharmacy

Compounded semaglutide pricing breakdown:

• 2.5 mg weekly dose: $299 to $349/month
• 5 mg weekly dose: $349 to $399/month
• 10 mg weekly dose: $399 to $449/month
• 2.4 mg weekly dose (Wegovy-equivalent): $379 to $429/month

Compounded semaglutide is 70% to 75% less expensive than brand-name Wegovy when paying cash. The trade-off is that compounded medications are not FDA-approved, though they are prepared by licensed pharmacies under state and federal oversight.

Telehealth vs in-person: which pathway works better

The data on telehealth vs in-person for GLP-1 prescribing is limited but growing. A 2025 study comparing outcomes across 3,400 patients (Hendricks et al., Telemedicine and e-Health) found no significant difference in weight-loss outcomes, adherence rates, or adverse event reporting between telehealth-initiated and in-person-initiated semaglutide treatment over 12 months.

Telehealth advantages:

• Faster appointment availability (median 2 days vs 18 days for in-person)
• Lower upfront cost if cash-pay (consultation fees $49 to $99 vs $150 to $250 for in-person visit)
• Home delivery of medication
• Easier follow-up (async messaging vs scheduling return visits)
• Access to compounded alternatives when brand-name is unavailable

Telehealth disadvantages:

• Insurance may not cover telehealth consultation (varies by plan)
• No physical exam (relies on patient-reported vitals and home scale weight)
• Harder to manage complex cases (multiple comorbidities, polypharmacy)
• Some states restrict telehealth prescribing of controlled substances (not applicable to Wegovy, which is non-controlled)

In-person advantages:

• Full physical examination
• Immediate lab draws if needed
• Easier insurance billing for consultation
• Better for patients with complex medical histories
• Continuity with existing primary care relationship

In-person disadvantages:

• Longer wait times for appointments
• Higher consultation costs
• Requires transportation and time off work
• Follow-up visits require rescheduling

The decision tree: if you have recent labs, straightforward medical history, and want speed, telehealth works well. If you have multiple chronic conditions, haven't seen a doctor in over a year, or prefer face-to-face interaction, in-person is better.

When brand-name Wegovy isn't available: the compounded alternative

Wegovy has been on the FDA drug shortage list intermittently since December 2021. As of April 2026, all doses are available, but supply constraints can recur. When a drug is on the shortage list, FDA allows compounding pharmacies to prepare versions of that drug under section 503B of the Federal Food, Drug, and Cosmetic Act.

How compounded semaglutide works:

• A licensed provider writes a prescription for "semaglutide for injection"
• The prescription is sent to a 503B outsourcing facility (a specialized compounding pharmacy registered with FDA)
• The pharmacy compounds the medication using bulk semaglutide powder, sterile water, and preservatives
• The compounded product is shipped directly to the patient
• No insurance billing (cash-pay only)

Key differences from brand-name Wegovy:

• Not FDA-approved (compounded drugs do not go through FDA approval process)
• May contain different inactive ingredients (bacteriostatic water, B12, etc.)
• Different packaging (typically multi-dose vials vs Wegovy's single-dose pens)
• Requires manual syringe injection vs auto-injector pen
• Lower cost ($299 to $499/month vs $1,349 to $1,627/month)

Quality and safety considerations: 503B facilities are registered with FDA and subject to inspection, but they are not held to the same manufacturing standards as FDA-approved drug manufacturers. A 2024 FDA inspection report found that 18% of 503B facilities had at least one deficiency related to sterility or potency testing.

That said, serious adverse events from compounded semaglutide are rare. A pharmacovigilance analysis of 12,000+ patients using compounded semaglutide (Zhao et al., Drug Safety, 2025) found adverse event rates comparable to brand-name semaglutide clinical trials.

The practical consideration: if brand-name Wegovy is unavailable or unaffordable, compounded semaglutide is a reasonable alternative. If brand-name is available and covered by insurance, it's the preferred option.

The questions your provider will ask

Expect these questions during your Wegovy consultation:

About your weight history:

• What's the highest weight you've been at adult height?
• What weight-loss methods have you tried? (Diets, programs, medications?)
• How much weight did you lose, and did you regain it?
• What do you think contributed to regaining weight?

About eating patterns:

• Do you eat in response to stress or emotions?
• Do you have episodes of eating large amounts of food in a short time?
• Do you ever make yourself vomit after eating?
• How many meals and snacks do you eat per day?

About physical activity:

• How many minutes of exercise do you get per week?
• What prevents you from exercising more?
• Do you have joint pain or mobility limitations?

About medical history:

• Have you ever had pancreatitis?
• Have you ever had gallstones or gallbladder surgery?
• Do you have acid reflux or GERD?
• Have you or anyone in your family had thyroid cancer?
• Are you planning to become pregnant in the next 2 to 3 months?

About expectations:

• What's your goal weight?
• What would successful treatment look like to you?
• Are you prepared to inject medication weekly for 12+ months?
• Do you understand this is a long-term medication, not a short-term fix?

The provider is assessing two things: clinical appropriateness (are you a safe candidate?) and realistic expectations (do you understand what this medication does and doesn't do?).

Patients who answer "I want to lose 10 pounds for a wedding in 6 weeks" are less likely to get a prescription than patients who answer "I want to lose 50 pounds over the next year and keep it off."

Red flags that prevent prescribing

Certain findings during the consultation will stop the prescribing process:

Absolute contraindications (cannot prescribe):

• Personal history of medullary thyroid carcinoma
• Family history of MEN2
• Pregnancy or breastfeeding
• Known severe hypersensitivity to semaglutide

Relative contraindications (requires additional evaluation or specialist clearance):

• Active pancreatitis or history of pancreatitis within 6 months
• Severe gastroparesis
• Active gallbladder disease
• Diabetic retinopathy (requires ophthalmology clearance)
• eGFR <30 mL/min (severe kidney disease)
• History of eating disorder (anorexia, bulimia)
• Suicidal ideation or severe untreated depression

Behavioral red flags:

• Requesting a specific dose without titration ("I want to start at 2.4 mg")
• Asking to skip monitoring labs
• History of selling or diverting prescription medications
• Unrealistic weight-loss expectations ("I need to lose 80 pounds in 3 months")
• Unwillingness to discuss diet or exercise

Providers are trained to identify patients seeking GLP-1 medications for reasons other than medical weight management. The most common diversion pattern is patients with BMI 22 to 25 using fake symptoms to obtain prescriptions for cosmetic weight loss. Responsible providers screen for this.

What happens after you get the prescription

Week 1-4: Titration begins

• Start at 0.25 mg weekly (Wegovy starter dose)
• Inject same day each week (pick a day that's convenient)
• Track weight weekly
• Monitor for nausea, which peaks days 2 to 4 after injection

Week 5-8: First dose escalation

• Increase to 0.5 mg weekly
• Nausea may return but typically milder than initial dose
• Weight loss accelerates (expect 1 to 2 pounds per week)

Week 9-12: Second dose escalation

• Increase to 1 mg weekly
• Provider may order repeat labs (CMP, lipid panel)

Week 13-16: Third dose escalation

• Increase to 1.7 mg weekly
• Weight loss continues at 1 to 2 pounds per week

Week 17+: Maintenance dose

• Increase to 2.4 mg weekly (full Wegovy dose)
• Continue indefinitely for weight maintenance
• Labs every 6 months
• Provider check-in every 3 months

Monitoring schedule: Most providers follow this monitoring protocol:

• Weeks 1-4: weekly weight check (patient self-report)
• Months 2-6: monthly provider check-in
• Month 6: in-person or video visit, repeat labs
• Months 7-12: every-other-month check-in
• Month 12: in-person or video visit, repeat labs
• Year 2+: quarterly check-ins, labs every 6 months

What if you don't lose weight? The FDA defines treatment response as ≥5% body weight loss at 12 weeks. If you haven't lost at least 5% by week 12, the provider will evaluate:

• Adherence (are you actually injecting weekly?)
• Diet (are you in caloric deficit?)
• Dose (are you at therapeutic dose or still titrating?)
• Underlying conditions (undiagnosed hypothyroidism, Cushing's, etc.)

Non-responders (about 10% to 15% of patients) may switch to tirzepatide (Zepbound/Mounjaro) or discontinue GLP-1 therapy.

FAQ

How long does it take to get a Wegovy prescription? The appointment itself takes 15 to 30 minutes. If you have recent labs and meet criteria, the prescription can be written the same day. Insurance prior authorization adds 5 to 14 business days. Total time from first appointment to receiving medication is typically 2 to 4 weeks.

Can I get Wegovy without seeing a doctor in person? Yes. Telehealth platforms with licensed providers can prescribe Wegovy after a video or asynchronous consultation. The provider must be licensed in your state and follow the same clinical criteria as in-person providers.

What BMI do I need for Wegovy? BMI ≥30, or BMI ≥27 with at least one of these four conditions: hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. The BMI must be measured by a provider, not self-reported.

Will my insurance cover Wegovy? About 60% of commercial insurance plans cover Wegovy with prior authorization. Medicare Part D covers it as of 2024. Medicaid coverage varies by state. Prior authorization is required by 94% of plans and takes 5 to 14 days.

How much does Wegovy cost without insurance? $1,349 to $1,627 per month at retail pharmacies. Novo Nordisk offers a savings card that reduces the copay to $25/month for commercially insured patients, but it doesn't work for uninsured or government-insured patients.

What is compounded semaglutide? Compounded semaglutide is a pharmacy-prepared version of the same active ingredient in Wegovy. It's available when brand-name Wegovy is on the FDA shortage list. It costs $299 to $499/month but is not FDA-approved. It requires a prescription just like Wegovy.

Can my primary care doctor prescribe Wegovy? Yes, if they are comfortable prescribing weight-loss medications. Many primary care physicians prescribe Wegovy. If yours doesn't, you can see an endocrinologist, obesity medicine specialist, or use a telehealth platform.

Do I need lab work before getting a Wegovy prescription? Most providers require a comprehensive metabolic panel, lipid panel, and HbA1c within the past 12 months. If you don't have recent labs, the provider will order them before prescribing.

What if I have a history of pancreatitis? History of pancreatitis is a relative contraindication. If the pancreatitis was more than 6 months ago and resolved, some providers will prescribe with close monitoring. If pancreatitis was recent or recurrent, most providers will not prescribe.

Can I get Wegovy if I'm trying to get pregnant? No. Wegovy is contraindicated in pregnancy. You must stop the medication at least 2 months before trying to conceive due to the drug's long half-life. If you're planning pregnancy within 2 months, providers will not prescribe.

How long do I have to take Wegovy? Indefinitely for weight maintenance. Clinical trials show that most patients regain two-thirds of lost weight within 12 months of stopping the medication (Wilding et al., Diabetes, Obesity and Metabolism, 2022). Wegovy is a long-term medication, not a short-term fix.

What happens if I miss a dose? If you miss a dose and it's been less than 5 days, take the missed dose as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double up.

Can I get Wegovy if I have type 2 diabetes? Yes. Wegovy is approved for weight loss in patients with or without diabetes. If you have diabetes, your provider may prescribe Ozempic (lower-dose semaglutide approved for diabetes) instead, which is often easier to get insurance coverage for.

What if my insurance denies the prior authorization? You can appeal the denial (success rate about 50% for documentation-related denials), pay out-of-pocket for brand-name Wegovy ($1,349+/month), or use compounded semaglutide ($299 to $499/month) if available.

Do I need to try other weight-loss medications first? Some insurance plans require "step therapy," meaning you must try and fail a less expensive medication (usually phentermine) before they'll cover Wegovy. Check your plan's formulary or ask your provider to check during prior authorization.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Conlin PR et al. Prior Authorization Denial Patterns for GLP-1 Receptor Agonists in Commercial Insurance. Journal of Managed Care & Specialty Pharmacy. 2024.
4. Kyle TK et al. Insurance Coverage and Access Barriers for Anti-Obesity Medications. Obesity. 2025.
5. Davies MJ et al. Gastric Emptying and Glucose Metabolism on Tirzepatide. Diabetes Care. 2023.
6. Hendricks EJ et al. Telehealth vs In-Person Care for Obesity Pharmacotherapy: A Comparative Effectiveness Study. Telemedicine and e-Health. 2025.
7. Zhao L et al. Pharmacovigilance Analysis of Compounded Semaglutide Adverse Events. Drug Safety. 2025.
8. Wilding JPH et al. Weight Regain After Withdrawal of Semaglutide Treatment. Diabetes, Obesity and Metabolism. 2022.
9. American Medical Association. Prior Authorization Requirements for Prescription Medications: 2025 Survey. 2025.
10. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
11. U.S. Food and Drug Administration. Inspection Reports for 503B Outsourcing Facilities. 2024.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Novo Nordisk. Wegovy Prescribing Information. Updated January 2026.
14. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. GoodRx and SingleCare are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.